Table S3 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

UID: 11184

Author(s): Adib, Elio, Klonowska, Katarzyna, Giannikou, Krinio, Do, Khanh T., Pruitt-Thompson, Solida, Bhushan, Ketki, Milstein, Matthew I., Hedglin, Jennifer, Kargus, Katherine E.*, Sholl, Lynette M., Tsuji, Junko, Hyman, David M., Sisk, Anne*, Shapiro, Geoffrey I., Vargas Alvarez, Hebert Alberto*, Harding, James J.*, Voss, Martin*, Iyer, Gopakumar Vasudeva*, Kwiatkowski, David J. * MSK affiliated

Description: Description from Figshare:

"Table S3. Toxicities (any level) occurring in at least two patients, grouped by CTCAE v4.0 categories. For patients with more than one adverse event per category, only the highest-grade event was counted."

Subject of Study

Homo sapiens

Subject(s)

Clinical Trial, Phase II

Everolimus

Neoplasms/drug therapy

TOR Serine-Threonine Kinases

Do you have or know of a dataset that should be added to the catalog? Let us know!